[
  {
    "ts": null,
    "headline": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
    "summary": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=6f04ba293e7bafcfb5742f154a80a10737b7e5f994c48bd5f4c727370ba6ed17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119599,
      "headline": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
      "id": 136789007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=6f04ba293e7bafcfb5742f154a80a10737b7e5f994c48bd5f4c727370ba6ed17"
    }
  },
  {
    "ts": null,
    "headline": "Advancing Cancer Research Brings New Hope for Patients Worldwide",
    "summary": "Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu",
    "url": "https://finnhub.io/api/news?id=e90ffbbb1f9a108a48e6589f09ac2a7c2994f01614980d5d4cd85acc1f09fd61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758115800,
      "headline": "Advancing Cancer Research Brings New Hope for Patients Worldwide",
      "id": 136789051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu",
      "url": "https://finnhub.io/api/news?id=e90ffbbb1f9a108a48e6589f09ac2a7c2994f01614980d5d4cd85acc1f09fd61"
    }
  },
  {
    "ts": null,
    "headline": "Berenberg Downgrades Merck (MRK)",
    "summary": "Berenberg Downgrades Merck (MRK)",
    "url": "https://finnhub.io/api/news?id=e3e6aba5306d1450962a4cf55eb0bd0a3501a3a31b2b335651dbb346419e725a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758110603,
      "headline": "Berenberg Downgrades Merck (MRK)",
      "id": 136788494,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e3e6aba5306d1450962a4cf55eb0bd0a3501a3a31b2b335651dbb346419e725a"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis",
    "summary": "Zacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks for investors.",
    "url": "https://finnhub.io/api/news?id=28f10a750657b7b89e15acabb331d19ea641d8e40ac2188e43327dd87b1b0aae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758106380,
      "headline": "The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis",
      "id": 136787412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks for investors.",
      "url": "https://finnhub.io/api/news?id=28f10a750657b7b89e15acabb331d19ea641d8e40ac2188e43327dd87b1b0aae"
    }
  },
  {
    "ts": null,
    "headline": "Workday to acquire Swedish AI company Sana for $1.1bn",
    "summary": "Through the acquisition, Workday aims to enhance its platform by integrating further AI capabilities.",
    "url": "https://finnhub.io/api/news?id=a5eb372ddc89cb8f568e9a79768e0aa2b335ee4b2856ed032a845de8fafbe826",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758103743,
      "headline": "Workday to acquire Swedish AI company Sana for $1.1bn",
      "id": 136787552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Through the acquisition, Workday aims to enhance its platform by integrating further AI capabilities.",
      "url": "https://finnhub.io/api/news?id=a5eb372ddc89cb8f568e9a79768e0aa2b335ee4b2856ed032a845de8fafbe826"
    }
  }
]